ID   J27-sB7
AC   CVCL_V057
SY   J27.2-sB7
DR   ATCC; CRL-2373
DR   Wikidata; Q54898459
RX   PubMed=7960968;
CC   Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Genetic integration: Method=Transfection; Gene=HGNC; 914; B2M.
CC   Genetic integration: Method=Transfection; Gene=HGNC; 4932; HLA-B (Note=Allele B*07, soluble form without TM and cytoplasmic domains).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Discontinued: ATCC; CRL-2373; true.
CC   Derived from site: In situ; Connective tissue; UBERON=UBERON_0002384.
CC   Cell type: Fibroblast; CL=CL_0000057.
CC   Breed/subspecies: C3H/An.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_K237 ! J27.2
SX   Male
AG   100D
CA   Spontaneously immortalized cell line
DT   Created: 16-04-14; Last updated: 10-09-24; Version: 11
//
RX   PubMed=7960968; DOI=10.1016/0198-8859(94)90074-4;
RA   Hiraki D.D., See-Tho K., Filvaroff E., Krishnaswamy S., de Bello W.,
RA   Taidi-Laskowski B., Grumet F.C.;
RT   "Bioengineered soluble HLA-B7. Genesis, characterization, and
RT   occurrence of dimerization.";
RL   Hum. Immunol. 40:235-246(1994).
//